Howdy, Stranger!

It looks like you're new here. If you want to get involved, click one of these buttons!

Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.
  • The Value Of Skill
    Hi Guys,
    The SPIVA reports have been issued for over a decade now, and the primary conclusions have remained constant during this entire period. Although percentages change depending on the market environment, less than half active mutual fund managers outperform applicable Indices.
    The law of conservation of returns demands this outcome since these active managers are themselves mostly the marketplace. Their cohort underperformance can be roughly estimated by considering the negative impact of costs and fees in the mix.
    SPIVA has done yeomen work in measuring the shortfall distributions in terms of asset classes (large/small, growth/value, US/International, government/corporate bonds, etc.). To fully appreciate and exploit the SPIVA studies, a nuanced review of the many SPIVA tables is required. I recommend that interested MFOers invest that required time.
    SPIVA does NOT compare, nor do they advise comparing, the bulk of their funds against a single reference standard. That’s wrongheaded. It is meaningless to contrast the returns of a Small Cap Value fund against the S&P 500 measure. These are obviously horses of a totally different color.
    The referenced ETF Trends article quoted the 86% record for only one year (2014) and only represented those funds that are assigned to the Large Cap category. The assumption that there are 8,000 funds in that grouping is wrong. In fact, there are typically slightly over 1,000 funds in that classification with a period survival rate that is less than 100%. The 8,000 assumption is grossly in error.
    Therefore, it’s incorrect to calculate that 1,120 active fund managers outdistanced the S&P 500. Also, using a single year’s performance data is similarly wrongheaded; returns are simply too jumpy and non-repeatable year-to-year to reliably use a single year for decision making.
    Even with this correction, a respectable number of active managers do indeed outdistance their benchmarks. But it is a narrow field, and Alpha (excess returns) is a vanishing quantity; a deeper examination of the SPIVA data sets quickly uncovers the disappearing Alpha phenomena. Superstars exist in all professional fields, although the stars’ output does erode with time. So too in the active fund management discipline.
    The erosion of overall Alpha these days is often attributed to the abundant expert, field leveling status of all fund managers. Jesse Livermore, Benjamin Graham, and Warren Buffett battled weaker opponents when establishing their superior records. The persistent perils are becoming a rare find.
    Please do not interpret this post as being generated by a fully committed Indexer. I am not. I am moving in the Indexer direction, but I still maintain over 30% of my portfolio under active fund management. Winners are out there.
    It is a challenge in a multi-dimensional world to identify the potential (never with certainty) winners. A history of positive Alpha is surely a good starting point. Style consistency and tenure are also contributing factors. Also smaller fund size allows the active manager to be more agile. Perhaps the single best discriminator is the overall cost of the fund. The most promising funds offer the lowest ownership costs.
    Several Vanguard studies that have been referenced on MFO earlier demonstrate a situational advantage for active management. Here are repeat Links to that work:
    http://www.vanguard.com/pdf/s356.pdf
    https://pressroom.vanguard.com/content/nonindexed/7.5.2013_The_bumpy_road_to_outperformance.pdf
    Admittedly, Vanguard is constantly grinding its axe, however, please checkout both the Vanguard studies and the SPIVA series. They’ll guide you in identifying solid active fund managers, without any guarantees of course. For example, the SPIVA data clearly show that an investor has a highly likelihood of selecting a superior Alpha fund manager for a Large Cap Value fund then for a Large Cap Growth fund.
    To end on a happy note, I’m sure you all know the story about what they call a mushroom who goes into a bar and orders drinks for the house. A fungi (a fun guy).
    Sorry about that. I suppose this tarnishes my image still further. My stock picking skills are no better than my joke selection skills. That’s yet another reason why I go the mutual fund route.
    Best Wishes.
  • Are Japan Mutual Funds Finally Getting Some Traction?
    Using a simple rule set and 10 mo simple moving average ( monthly basis ) applied to the Nikkei index and Japan Govt bonds, the investment returns over the last 2.5 lost decades of the Japan experience could have been improved and risk mitigated https://docs.google.com/presentation/d/1Sn6BKRCKRU5tensBDFTkJXI3v2wRQ4M1bt8VoIM2Zmc/edit?usp=sharing
  • Are Japan Mutual Funds Finally Getting Some Traction?
    FYI: Japan mutual funds have lagged the S&P 500 since the market bottom in 2011, but they're outperforming this year. Which of these two would have made a smart investment: Putting $10,000 into the average Japan fund on Dec. 31, 1999, or putting that amount into the S&P 500?
    Regards,
    Ted
    http://license.icopyright.net/user/viewFreeUse.act?fuid=MTkxMzE4MzM=
  • Biotech Stocks On Pace To Snap 8-day Win Streak As Warnings Abound
    @Ted
    Agree. A blip right now.
    Memory recall (semi-valid) from last Thursday; SBIO was up about 3.65%, gave most of that back on Friday when other areas were stronger. Down about 1.8% as of this pre-noon write. Note that SBIO are baby bio-techs and likely not reflected within the overall bio area as with your holding of Fido bio fund, which holds more of the established companies.
    Watching; but we do not currently have any holding in SBIO.
    Thinking we'll still make some more $'s in this area, eh?
    Regards,
    Catch
  • Biotech Stocks On Pace To Snap 8-day Win Streak As Warnings Abound
    FYI: )—Biotech stocks slumped Monday, with the largest biotech ETF down about 1.7% and on track to snap an eight-session winning streak.
    Regards,
    Ted
    http://www.marketwatch.com/story/biotech-stocks-on-pace-to-snap-8-day-win-streak-as-warnings-abound-2015-03-23/print
    Actually days like this help shake out some of the weak sisters , and short-term investors taking porfits. Long-term I'm still very bullish on biotech's & general healthcare.
    Regards,
    Ted
  • The Value Of Skill
    FYI: 2014 was an extraordinarily difficult year for active equity managers, especially in the U.S. market; our year-end SPIVA report, e.g., showed that 86% of large-cap equity funds underperformed the S&P 500. This observation is hardly unique, nor original to us. What’s unusual about 2014’s results is that the rate of failure was extraordinarily high — between 2000 and 2013, on average “only” 58% of large-cap managers underperformed, as against 2014’s 86%.
    Regards,
    Ted
    http://www.etftrends.com/2015/03/indexology-the-value-of-skill/
  • BBALX, GBMFX and 3/1/15 commentary
    Hi NumbersGal,
    In the World Allocation space, I would take a serious look at MTOIX ($500 min in Fidelity retirement accounts + TF) and HCOYX ($100 min in Scottrade accounts + TF, $500 min in TDA retirement accounts + TF).
    Kevin
  • Performance Of Actively Managed Versus Index Funds: THE Vanguard Case
    FYI: John C. Bogle: “Well I don’t run Vanguard any longer, but I will take plenty of responsibility for having those active funds in all of the years I ran it. And the answer to that is really a couple of things. One, a lot of investors, no matter how persuasive the case for indexing is, and it’s overpoweringly persuasive, just don’t quite get it. They want a little more activity. They want something to watch. Index funds, as you all know, are roughly as exciting as watching paint dry or maybe watching the grass grow. They create great returns but they’re not that exciting. So what we tried to do and what I tried to do personally was pick good managers, and that’s very, very hard to do. I want to be clear on that, and I have some hits and some runs and some errors in that category, have funds with multiple managers, so you get a much broader diversification, which is not unlike an index fund. . . . [for example, take] our Windsor II fund. It’s a large cap value fund. And it has five different managers. I think that’s the number now. And so you are going to tend to have a value average return for that fund. And then, actually, make sure you have the other two big advantages of indexing, or three really, no sales commissions, very low expense ratios, because I negotiated with all those advisors and got those fees as low as I could possibly get them, and hire advisors with low portfolio turnover. An article was done by some professors at Duke University about a year ago and they showed that our active managers in the life of the index fund actually did a hair better than the index fund. [Reinker and Tower (2005)]. On the other hand if we had started the comparison a little bit later, the active managers would have done a little bit worse. But I think it’s a valid strategy. What can I do and tell you? I’m still 80% indexed.” [Bogle (2006)].
    As if by reply, Dan Wiener, editor of the FFSA Independent Guide to the
    Vanguard Funds, writes:
    “Vanguard wants you to ‘believe’ in indexing. Your faith in indexing is the cornerstone of their business. But it’s a lie. And your trust could cost you…plenty!. … Indexing doesn’t work for you. It works for them. The big famous Index funds at
    1
    Vanguard have chronically underperformed over the last few years, exposing conservative investors to the worst risks of bear markets. But Vanguard knows investors who plunk money into an index become “passive.” Their money goes “dead.” And Vanguard never has to worry about these clients getting antsy. Indexing is a great business—but it’s a lousy investment
    Regards,
    Ted
    http://public.econ.duke.edu/Papers//PDF/0419CHAPTER_12_TOWER_working_paper_version.pdf
  • Mutual Funds Pick Year When S&P 500 Is Up 2% To Beat Market
    My Mutual Funds & ETFs (including Bonds) +4.4% ytd..Killing my individual stocks, but lots of time to rally plus many good Divs coming from stocks rest of year
    In all... good (enough) first Quarter...VTSMX +3.5%
  • Mutual Funds Pick Year When S&P 500 Is Up 2% To Beat Market
    FYI: -- Good news for investors: far more mutual funds are beating the market than last year. The bad news is that stocks are returning one-tenth as much.
    Regards,
    Ted
    http://www.bloomberg.com/news/articles/2015-03-17/mutual-funds-pick-year-when-s-p-500-is-up-1-to-beat-the-market
  • Barry Ritholtz: Admitting My 2014 Mistakes
    FYI: 2014 is behind us, and before the first quarter sneaks by, I am obligated to offer my annual admissions of error.
    Regards,
    Ted
    http://www.washingtonpost.com/business/get-there/admitting-my-2014-mistakes/2015/03/20/0d539fd2-ccc0-11e4-8c54-ffb5ba6f2f69_story.html
  • Jsason Zweig: While Regulators Fiddle, Avoid Getting Burned
    "The Dodd-Frank financial-regulatory law of 2010 required the SEC to study the issue but didn’t mandate a particular conclusion."
    2015: study-in-progress.......... is not a study in progress.
  • "To be or not to be"... MAPIX
    From the Sept 2014 MAPIX fact sheet (and as currently stated on the MAPIX home page, and presumably in the fund's prospectus):
    Investment Objective
    Total return with an emphasis on providing current income. (my emphasis)
    @Maurice @Old_Joe
    After assessing the past half-year of performance, how would you rate the fund in terms of following its stated investment objective: (1) success, (2) short of the mark, (3) fail?
    Strategy
    {..} the Mathews Asia Dividend Fund seeks to achieve its investment objective by investing at least 80% of its total assets {...} in income-producing securities of companies located in Asia, {...}. The Fund seeks to provide a level of current income that is higher than the yield generally available in Asian equity markets over the long term. (my emphasis)
    @Maurice @Old_Joe
    After assessing the past half-year of performance, how would you rate the fund in terms of adhering to its stated strategy for achieving its investment objective: (1) success, (2) short of the mark, (3) fail?
    If one had purchased shares on the Sept dvd ex-date, the dvd distributed for the past 6 months would be 0.01855 (and no CGs to reinvest); using that ex-date NAV, one's dvd yield, annualized, would be ___? (hmm, I had no idea "the yield generally available in Asian equity markets" had declined so precipitously)
  • Paul Merriman: This 4-Fund Combo Wallops The S&P 500 Index
    Valpo....I could I ever forget a small college we used to beat by 50 back in my day, Spokane is what state, I forgot?
  • EM Declines and Subsequent Allocation
    Yes, I own much less in EM than I did only last year. My only pure play is SFGIX: 2.69% of portfolio. TRAMX (frontier), 5.95% of portfolio, PRASX is 15.06% of portf....
    M* X-ray tells me I own 25% foreign equities. Though I pulled out of PRESX, I still have 3.26% in developed Europe, and 0.7% in emerging Europe. And 13.1% developed Asia, 15.53% in Emerging Asia.
    Canada and US: 55.01%
    Bonds of all sorts: 37% of total.
  • "To be or not to be"... MAPIX
    Hi OJ. Here are some numbers through February...sparse category, actually:
    image
    And against peers past 12 months...
    image
  • "To be or not to be"... MAPIX
    If you're the Federales, then where's your badges??? So, MAPIX declares a div, of $0.01855 cents. Where I come from, that's less than .02 cents. That's pretty LEAN. Anyway, I'm already out of MAPIX and Matthews, as of early February.
  • EM Declines and Subsequent Allocation
    I still say Abbott Labs (ABT) is the most enjoyably boring play on EM, with about 50% of revenues from EM and the stock is conservative to put it lightly. International Flavors and Fragrances, which has been around for 125 years or so, is also about 50% EM. (IFF). I own both. As for EM, I continue to own RIMIX and a few individual names but less EM than I used to.
    EM I think remains a compelling long-term theme but it's not been a good few years. I mean look at Wintergreen's attempts to play the EM consumer, with Macau stocks (obliterated) and luxury goods (which were hurt by the crackdown in Asia on luxury gifting.)
    SFGIX is probably the most interesting to me from the standpoint of the growth and income mix.